Background/Aims The data on the prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in patients with inflammatory bowel disease (IBD) are conflicting. The present systematic review was thus conducted to study the prevalence of HBV and HCV markers in patients with IBD.
Methods A comprehensive literature search of 3 databases was conducted from 2000 to April 2022 for studies evaluating the prevalence of HBV or HCV in patients with IBD. Pooled prevalence rates across studies were expressed with summative statistics.
Results A total of 34 studies were included in the final analysis. The pooled prevalence of hepatitis B surface antigen (HBsAg) and hepatitis B core antibodies were 3.3% and 14.2%, respectively. In HBsAg positive IBD patients, hepatitis B e antigen positivity and detectable HBV DNA were seen in 15.3% and 61.0% of patients, respectively. Only 35.6% of the IBD patients had effective HBV vaccination. The pooled prevalence of anti-HCV and detectable HCV RNA were 1.8% and 0.8%, respectively. The pooled prevalence of markers of HBV infection was higher in Asian studies, while the prevalence of markers of HCV infection was higher in European studies. The prevalence of viral hepatitis markers was similar between IBD patients and the general population and that between ulcerative colitis and Crohn’s disease.
Conclusions The prevalence of markers of viral hepatitis remains same as the general population with significant regional variations, although the quality of evidence remains low due to publication bias. Only a small proportion of IBD patients had an effective HBV vaccination, requiring improvement in screening and vaccination practices.
Citations
Citations to this article as recorded by
Hepatobiliary and pancreatic manifestations in inflammatory bowel disease: an umbrella review of meta-analyses Runsheng Hong, Zhixue Li, Meng Li, Yun Dai Therapeutic Advances in Gastroenterology.2025;[Epub] CrossRef
Serological Assessment of Hepatitis in Patients with Inflammatory Bowel Disease in Taiwan: A Retrospective Cohort Analysis Yueh-An Lee, Hsu-Heng Yen, Yang-Yuan Chen Life.2025; 15(6): 893. CrossRef
British Society of Gastroenterology guidelines on inflammatory bowel disease in adults: 2025 Gordon W Moran, Morris Gordon, Vassiliki Sinopoulou, Shellie J Radford, Ana-Maria Darie, Sudheer Kumar Vuyyuru, Laith Alrubaiy, Naila Arebi, Jonathan Blackwell, Thomas D Butler, Thean Chew, Michael Colwill, Rachel Cooney, Gabriele De Marco, Said Din, Shah Gut.2025; 74(Suppl 2): s1. CrossRef
Management of ulcerative colitis in Taiwan: consensus guideline of the Taiwan Society of Inflammatory Bowel Disease updated in 2023 Hsu-Heng Yen, Jia-Feng Wu, Horng-Yuan Wang, Ting-An Chang, Chung-Hsin Chang, Chen-Wang Chang, Te-Hsin Chao, Jen-Wei Chou, Yenn-Hwei Chou, Chiao-Hsiung Chuang, Wen-Hung Hsu, Tzu-Chi Hsu, Tien-Yu Huang, Tsung-I Hung, Puo-Hsien Le, Chun-Che Lin, Chun-Chi Lin Intestinal Research.2024; 22(3): 213. CrossRef
Assessing the associations of inflammatory bowel disease and hepatitis B virus infections with two-sample bidirectional mendelian randomization Ping Han, Chaohui Wang, Yan Qiu Critical Public Health.2024; 34(1): 1. CrossRef
Associations between chronic hepatitis B infection and inflammatory bowel diseases in East Asian populations Haiyan Ye, Deqin Wei, Yike Huang Future Virology.2024; 19(16-18): 563. CrossRef
Protective role of flavonoids quercetin and silymarin in the viral-associated inflammatory bowel disease: an updated review Elham Zarenezhad, Hussein T. Abdulabbas, Ahmed Shayaa Kareem, Seyed Amin Kouhpayeh, Silvia Barbaresi, Sohrab Najafipour, Abdulbaset Mazarzaei, Mitra Sotoudeh, Abdolmajid Ghasemian Archives of Microbiology.2023;[Epub] CrossRef
Infectious complications in patients with inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 8th Asian Organization for Crohn’s and Colitis meeting Yu Kyung Jun, Seong-Joon Koh, Dae Seong Myung, Sang Hyoung Park, Choon Jin Ooi, Ajit Sood, Jong Pil Im Intestinal Research.2023; 21(3): 353. CrossRef